How a typographical error between amyloid-beta (Aβ) and amyloid-Eszett (Aß) distorted Alzheimer's research for years, with bibliometric evidence of its impact.
Exploring how riluzole, an ALS drug, shows promise in treating Alzheimer's disease by targeting glutamate regulation and neuroprotection.
Discover how a single D-glutamate molecule transforms Aβ42 into stabilized toxic oligomers, revealing new insights into Alzheimer's disease pathology.
Discover how Aβ−3–40, a novel cerebrospinal fluid biomarker, is revolutionizing early Alzheimer's disease detection through advanced biochemical analysis.
Discover how longitudinal MRI studies in transgenic mice are revolutionizing our understanding of beta-amyloid plaque development in Alzheimer's disease.
Explore the groundbreaking experimental approaches revolutionizing Alzheimer's disease research and treatment in 2025.
Exploring riluzole, an FDA-approved ALS drug, as a potential treatment for Alzheimer's disease by targeting glutamate dysregulation.
How blood-based biomarkers are transforming Alzheimer's diagnosis and treatment with groundbreaking research from Stanford and others.